Strengthening Drug Discovery Capabilities and Building a Global R&D Organization
First written in FY2016. 14 of 24 entries say "Advanced", first in FY2017. Latest entry: FY2026.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
5 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The new broad-spectrum insecticide cybenzoxasulfyl completed its domestic agricultural chemical registration application in November 2025. It also completed a registration application in South Korea in November 2025, and development is being considered in India and other countries and regions with expected market potential.」
For cybenzoxasulfyl, agricultural chemical registration applications were completed in Japan and South Korea, and the company progressed to preparations for commercialization after registration and consideration of global development in India and elsewhere. - 2026-05-13AdvancedRevision of earnings forecasts
「The main initiatives during the fiscal year included completing registration applications in Japan and South Korea for the new active ingredient cibenzoquasulfyl, whose development the Company had been pursuing in-house.」
Research, development, and commercialization of the new active ingredient cibenzoquasulfyl progressed through completion of registration applications in Japan and South Korea. - FY2026-H1AdvancedAnnual report
「Through open innovation with the RIKEN Center for Sustainable Resource Science, we advanced initiatives to create new sources of revenue, including filing a patent application toward commercialization of production technologies for high-value-added compounds using materials derived from natural products.」
Production technology development using materials derived from natural products through open innovation with RIKEN progressed to the filing of a patent application toward commercialization. - FY2025AdvancedAnnual report
「The new broad-spectrum insecticide cybenzoxasulfyl (development code: NNI-2101) was submitted again this year to practical efficacy trials for new agricultural chemicals conducted by the Japan Plant Protection Association, and effective test cases required for an agricultural chemical registration application were accumulated. These findings demonstrated the product's characteristics, including a broad insecticidal spectrum, efficacy against pests with reduced sensitivity to existing products, and excellent translaminar activity. An agricultural chemical registration application is scheduled for 2025.」
For NNI-2101, test cases were accumulated through practical efficacy trials, and plans were described to file an agricultural chemical registration application in 2025 and pursue global development in South Korea, India and elsewhere. - FY2024-Q2AdvancedAnnual report
「In India, the consolidated subsidiary Nichino India Pvt. Ltd. registered a new combination formulation of the new paddy-rice insecticide benzpyrimoxan, and a multipurpose plant capable of manufacturing multiple active ingredients was completed. The plant is scheduled to begin operations during the current fiscal year.」
The registration of a new benzpyrimoxan combination formulation and completion of a multipurpose plant capable of manufacturing multiple active ingredients represent progress in R&D, commercialization and the overseas production structure. - FY2023AdvancedAnnual report
「Development activities toward agricultural chemical registration of the new broad-spectrum insecticide NNI-2101 are progressing, including its submission to practical efficacy trials for new agricultural chemicals conducted by the Japan Plant Protection Association.」
NNI-2101 was submitted to practical efficacy trials for new agricultural chemicals, and consideration began for global development in South Korea, India and elsewhere. Development is also being considered for 1 new insecticide and 1 fungicide. - FY2023-Q2AdvancedAnnual report
「The Group's main initiative during the second quarter of the current cumulative consolidated period was the launch of full-scale sales of the new paddy-rice insecticide benzpyrimoxan in India, together with technical extension activities to expand sales.」
Benzpyrimoxan progressed to the stage of full-scale sales in India and the implementation of technical extension activities. - FY2022AdvancedAnnual report
「From the current consolidated fiscal year, domestic development of the new broad-spectrum insecticide NNI-2101 began. In addition, development is being considered for a new pipeline comprising 2 insecticides and 1 fungicide.」
Domestic development of the new broad-spectrum insecticide NNI-2101 began, and development is being considered for a pipeline comprising 2 insecticides and 1 fungicide. - FY2022-Q3RestatedAnnual report
「In September 2021, we decided to advance development of a new insecticide further toward registration.」
The decision to advance development of the new insecticide further toward registration was reaffirmed. The decision itself had already been described in the previous filing. - FY2022-Q2AdvancedAnnual report
「In September 2021, we decided to advance development of a new insecticide further toward registration.」
It describes the specific progress of a decision made in September 2021 to advance development of a new insecticide further toward registration. - FY2022-Q1AdvancedAnnual report
「In May this year, we began selling the new paddy rice insecticide benzpyrimoxan, marketed as Orchestra, which obtained pesticide registration in Japan in September last year.」
Following agricultural chemical registration in Japan, benzpyrimoxan reached the stage of launching sales as Orchestra on 25 May 2021. - FY2021AdvancedAnnual report
「In Japan, Orchestra Flowable and Orchestra Dust DL obtained agricultural chemical registration in September 2020, earlier than usual, after their novel mode of action was recognized and they were granted priority review. Orchestra Flowable began sales in May 2021. In India, registration is expected in 2022, and an import tolerance application in the United States is planned during 2021.」
Benzpyrimoxan obtained agricultural chemical registration in Japan and began sales in May 2021, while plans were also indicated for registration in India and an application in the United States. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the nine months ended the third quarter were ¥3,053 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
It stated that there were no material changes in R&D activities and recorded ¥3,053 million in R&D expenditure, primarily for the agricultural chemicals business. - FY2021-Q2AdvancedAnnual report
「Benzpyrimoxan, a new insecticide for paddy rice independently invented by the company and for which applications for agricultural chemical registration were filed in Japan and India in February 2019, obtained agricultural chemical registration in Japan on 14 September of this year under the domestic product name Orchestra. Sales are scheduled to begin in May 2021.」
It obtained agricultural chemical registration for benzpyrimoxan in Japan and indicated that sales are scheduled to begin in May 2021. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the three months ended the first quarter were ¥851 million for the group as a whole, mainly related to the agrochemicals business. There were no material changes in the status of the group's research and development activities during the period.」
It recorded ¥851 million in R&D expenditure and explained that there were no material changes in the status of R&D activities. - FY2020-Q3RestatedAnnual report
「Total R&D expenditure for the Group during the first quarter of the current cumulative consolidated period was ¥1,051 million, primarily for the agricultural chemicals business. There were no material changes in the status of the Group's R&D activities during the period.」
It recorded first-quarter R&D expenditure of ¥1,051 million and explained that there were no material changes in the status of R&D activities. - FY2020-Q1RestatedAnnual report
「Total R&D expenditure for the Group during the third quarter of the current cumulative consolidated period was ¥3,030 million, primarily for the agricultural chemicals business. There were no material changes in the status of the Group's R&D activities during the period.」
It recorded ¥3,030 million in R&D expenditure and explained that there were no material changes in the status of R&D activities. - FY2019-Q4RestatedAnnual report
「Total R&D expenditure for the Group during the second quarter of the current cumulative consolidated period was ¥2,151 million, primarily for the agricultural chemicals business. There were no material changes in the status of the Group's R&D activities during the period.」
It recorded ¥2,151 million in R&D expenditure and explained that there were no material changes in the status of R&D activities. - FY2019-Q3RestatedAnnual report
「Total R&D expenditure for the Group during the first quarter of the current cumulative consolidated period was ¥1,218 million, primarily for the agricultural chemicals business. There were no material changes in the status of the Group's R&D activities during the period.」
It recorded ¥1,218 million in R&D expenditure and explained that there were no material changes in the status of R&D activities. - FY2018AdvancedAnnual report
「Total R&D expenditure for the Group was ¥4,690 million. Development of benzpyrimoxan (NNI-1501), a new insecticide for paddy rice being developed simultaneously in Japan and India, is proceeding on schedule in cooperation with Nichino India Pvt. Ltd., and registration applications in Japan and India are expected to be filed during the year.」
The company describes specific progress in global R&D and registration, including ¥4,690 million in R&D expenditure and expected simultaneous registration applications for benzpyrimoxan in Japan and India. - FY2019-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
It explains that there have been no material changes in R&D activities. - FY2018-Q4RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
It explains that there have been no material changes in R&D activities. - FY2017AdvancedAnnual report
「We aim to improve the quality and expand the scale of our drug discovery capabilities by improving discovery and development methods and strengthening our personnel. Together with our overseas group companies, we will also strengthen our global R&D structure by enhancing overseas evaluation and registration systems, with the aim of maximizing and accelerating the development of our internally developed products.」
Specific progress in R&D and registration is described, including simultaneous applications in Japan and India for benzpyrimoxan and the expected registration and launch of pyraziflumid in the first half of 2018. - FY2016First statedAnnual report
「We aim to improve the quality and expand the scale of our drug discovery capabilities by improving discovery and development methods and strengthening our personnel. Together with our overseas group companies, we will also strengthen our global R&D structure by enhancing overseas evaluation and registration systems, with the aim of maximizing and accelerating the development of our internally developed products.」
Measures are being implemented to strengthen R&D capabilities by improving discovery and development methods, strengthening personnel, and enhancing overseas evaluation and registration systems.